摘要
目的:观察氯沙坦对原发性高血压患者血管内皮功能及肾功能的保护作用。方法:对40例轻、中度原发性高血压患者(观察组),予以氯沙坦片50mg,qd,口服,血压下降不理想增加至100mg,qd,连用16周。观察治疗前、后患者血压变化,并检测肱动脉内皮舒张功能(FMD)及尿微量白蛋白(U-MALB)、β2-微球蛋白(β2-MG)含量的变化和不良反应。另选30例健康体检者作为对照组。结果:治疗前,观察组患者肱动脉FMD较对照组明显降低,尿U-MALB和β2-MG含量均较对照组明显升高(均P<0.01);经氯沙坦治疗16周后,观察组患者收缩压和舒张压均控制正常,肱动脉FMD较治疗前明显升高,尿U-MALB和β2-MG含量均较治疗前明显降低(均P<0.01)。但与对照组比较,差异仍有统计学意义(P<0.05)。治疗过程中未见明显不良反应发生。结论:原发性高血压患者存在血管内皮功能障碍和肾脏功能损害,氯沙坦具有良好降压效果,有改善原发性高血压患者内皮功能和保护肾功能作用。
OBJECTIVE： To investigate the protective effect of losartan on endothelial and kidney functions in patients with essential hypertension. METHODS： 40 patients with mild or moderate primary hypertension （observation group） were given losartan 50 mg-d orally to 100 mg-d if the blood pressure was not controlled well for 16 weeks. The changes of blood pressure were observed before and after therapy. The changes of FMD, U-MALB level, β2-MG content and ADR were determined. 30 healthy people were set as control group. RESULTS： The level of FMD in observation group was significantly lower than in control group, but the levels of U-MALB and β2-MG were opposite （both P〈0.01）. 16 weeks after treatment, the systolic and diastolic pressure of observation group were controlled well, and the FMD increased significantly than pre-therapy, but the levels of U-MALB and fl2-MG were opposite （all P〈0.01）, and increased significantly than control group （P〈0.05）. No ADR was found during treatment. CONCLUSIONS： There are dysfunction of endothelial and kidney in patient with essential hypertension. Losartan can well decrease the blood pressure, improve the endothelial and kidney function.
出处
《中国药房》
CAS
CSCD
2012年第12期1106-1107,共2页
China Pharmacy
关键词
原发性高血压
氯沙坦
血管内皮功能
肾功能
Essential hypertension
Losartan
Endothelial function
Kidney function
